• KimHyun JungHJDepartment of Biopharmaceutical Chemistry, Kookmin University, Seoul 02707, Korea.Biopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, Seoul 02707, Korea.Antibody Research Institute, Kookmin University, Seoul 0.
• Department of Biopharmaceutical Chemistry, Kookmin University, Seoul 02707, Korea.
• Medicina (Kaunas). 2022 May 11; 58 (5).

AbstractOvarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.

23 keywords...

hide…